As FDA develops regulations for Liquid Chromatography-Mass Spectrometry tests, the agency says it is helpful for sponsors to understand the agency's current thinking on multiplex tests systems and In Vitro Diagnostic Multivariate Index Assays, since they are currently the closest diagnostic tools to LC-MS tests. After the meeting FDA's Julia Lathrop and Doug Jeffrey spoke to The Gray Sheet about their initial thoughts.
